查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1679373

全球多巴胺促效剂市场：市场规模、市场份额、趋势分析（按药物、给药途径、应用、分销管道和地区）、按细分市场预测（2025-2030 年）

Dopamine Agonist Market Size, Share & Trends Analysis Report By Drug (Non-ergot Dopamine Agonists, Ergot Alkaloids), By Route Of Administration (Oral, Injectable), By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 153 Pages | 商品交期: 2-10个工作天内

价格

多巴胺促效剂市场的成长与趋势：

根据 Grand View Research, Inc. 的最新报告，全球多巴胺促效剂市场规模预计到 2030 年将达到 18.3 亿美元，预测期内的复合年增长率为 5.70%。神经系统治疗对多巴胺促效剂（包括麦角生物碱和非麦角多巴胺促效剂）的需求为製药业创造了重大机会。这些药物已被证明可有效治疗帕金森氏症、不安腿症候群（RLS）和高催乳素血症等疾病，正在推动市场扩张。儘管麦角衍生的多巴胺促效剂早已在临床上使用，但非麦角多巴胺促效剂由于安全性和耐受性的改善而越来越受到青睐。随着支持多巴胺促效剂疗效的临床证据不断增加，促效剂在治疗运动障碍的应用也日益增加。

口服和注射製剂的开发进一步扩大了治疗的机会和患者的偏好。口服多巴胺促效剂广泛用于治疗巴金森氏症和RLS等慢性病，具有给药方便、长期坚持等特性。另一方面，注射剂在疾病的急性和晚期的治疗中发挥重要作用，需要立即产生持久的效果。随着製药公司专注于开发创新的药物输送方法，市场将进一步成长。

Teva Pharmaceutical Industries Ltd.、GSK plc.、Supernus Pharmaceuticals, Inc.、H. Lundbeck A/S、Amneal Pharmaceuticals LLC、UCB Pharma、Novartis AG、VeroScience LLC.、Pfizer Inc. 和 Boehringer Ingelheim Pharmaceuticals, Inc. 等製药公司正在积极为扩张市场扩张市场做出贡献。这些公司致力于研究和开发，以提高疗效、安全性和患者依从性，进一步促进这些治疗方法的采用。

零售药局在多巴胺激动剂的分销中发挥越来越重要的作用，特别是用于慢性病管理的口服促效剂。这些药局不仅提供便利的药物取得管道，还提供病患教育和咨询服务，以确保病患依从性和最佳治疗效果。零售药局是长期患者照护的关键组成部分，因为它们可以提供持续的药物补充和支持。

密切监测至关重要，特别是在治疗的早期阶段。例如，帕金森氏症患者通常在医院的监督下开始接受治疗，然后才转入门诊治疗。随着患者病情稳定，零售药局和专科药局成为持续用药和支持服务的主要资讯来源，而不会中断慢性神经系统疾病的治疗。

随着多巴胺促效剂的需求不断增加，供应链管理和药品分销等挑战也随之出现。确保口服和注射药物的稳定供应需要强大的物流基础设施和注重病患教育，以最大限度地提高依从性和治疗效果。此外，持续对研发的投资，特别是在新型给药系统的研发上，为製药公司提供了满足更广泛患者群体和改善治疗效果的机会。

多巴胺促效剂市场：概述

  • 2024 年，非麦角多巴胺促效剂占据市场主导地位，巩固了其作为神经系统疾病首选治疗方案的地位。其良好的安全性、增强的耐受性和不断提高的临床接受度使其成为同类药物中的领先治疗方法。
  • 到 2024 年，口服药物将占据市场主导地位。口服製剂因其方便、长期坚持的优势以及对治疗帕金森氏症、不安腿综合症（RLS）和高催乳素血症等慢性病的有效效果而受到广泛青睐。
  • 到 2024 年，零售药局将成为主要分销管道。零售药局提供的服务更加便捷，易于获取，使其成为使用多巴胺促效剂的患者的主要网路基地台。
  • 北美凭藉其发达的医疗保健基础设施、对神经系统疾病的高度认识以及先进的治疗方案而引领市场。

目录

第一章 分析方法及范围

第 2 章执行摘要

3. 多巴胺促效剂市场：变数、趋势和范围

  • 母市场展望
  • 附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 多巴胺促效剂市场：分析工具
    • 波特五力分析
    • PESTEL 分析
  • 管道分析
    • 第 1 阶段
    • 第 2 阶段
    • 第 3 阶段

第 4 章 多巴胺促效剂市场：药物特定估计与趋势分析

  • 多巴胺促效剂市场：细分仪表板（按药物）
  • 多巴胺促效剂市场：药物趋势分析（2024 年和 2030 年）
  • 非麦角多巴胺促效剂
  • 麦角生物碱

第 5 章 多巴胺促效剂市场：按应用的估计和趋势分析

  • 多巴胺促效剂市场：细分仪表板、按应用划分
  • 多巴胺促效剂市场：按应用分類的趋势分析（2024 年和 2030 年）
  • 帕金森氏症
  • 不宁腿(RLS)
  • 高催乳素血症
  • 其他的

第六章 多巴胺促效剂市场：依给药途径的估计与趋势分析

  • 多巴胺促效剂市场：细分仪表板，依给药途径划分
  • 多巴胺促效剂市场：按给药途径分類的趋势分析（2024 年和 2030 年）
  • 口服
  • 注射
  • 其他的

第 7 章 多巴胺促效剂市场：按分销管道进行的估计和趋势分析

  • 多巴胺促效剂市场：细分仪表板、通路
  • 多巴胺促效剂市场：按分销管道分類的趋势分析（2024 年和 2030 年）
  • 零售药局
  • 医院药房
  • 其他药局

第 8 章 多巴胺促效剂市场：按地区分類的估计和趋势分析

  • 多巴胺促效剂市场占有率（按地区划分） (2024 年和 2030 年)
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 参与企业概况
  • 财务表现
  • 产品基准评效
  • 公司市场占有率分析（2024 年）
  • 公司简介
    • Teva Pharmaceutical Industries Ltd
    • GSK plc.
    • Supernus Pharmaceuticals, Inc.
    • H. Lundbeck A/S
    • Amneal Pharmaceuticals LLC
    • UCB Pharma
    • Novartis AG
    • VeroScience LLC.
    • Pfizer Inc.
    • Boehringer Ingelheim Pharmaceuticals, Inc.

第 10 章 结论

Product Code: GVR-4-68040-531-1

Dopamine Agonist Market Growth & Trends:

The global dopamine agonist market size is anticipated to reach USD 1.83 billion by 2030 and is projected to grow at a CAGR of 5.70% during the forecast period, according to a new report by Grand View Research, Inc. The demand for dopamine agonists in neurological treatments, including ergot alkaloids and non-ergot dopamine agonists, is creating significant opportunities in the pharmaceutical sector. These drugs, which have demonstrated effectiveness in managing conditions like Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia, are driving market expansion. Ergot-derived dopamine agonists have long been used in clinical practice, while non-ergot dopamine agonists are gaining preference due to their improved safety profiles and tolerability. With growing clinical evidence supporting their efficacy, the acceptance of dopamine agonists in managing movement disorders continues to rise.

The development of oral and injectable formulations further broadens treatment accessibility and patient preference. Oral dopamine agonists are widely used for chronic conditions like Parkinson's disease and RLS, allowing for convenient administration and long-term adherence. Injectable formulations, on the other hand, play a crucial role in managing acute or advanced-stage cases where immediate and sustained drug action is required. With pharmaceutical companies focusing on developing innovative drug delivery methods, the market is poised for further growth.

Pharmaceutical companies such as Teva Pharmaceutical Industries Ltd., GSK plc., Supernus Pharmaceuticals, Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, UCB Pharma, Novartis AG, VeroScience LLC., Pfizer Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. are actively contributing to the expansion of the market. These companies are engaged in research and development efforts to improve drug efficacy, safety, and patient compliance, further driving the adoption of these therapies.

Retail pharmacies play an increasing role in the distribution of dopamine agonists, particularly for oral formulations used in chronic disease management. These pharmacies offer not only easy access to medications but also patient education and counseling services to ensure adherence and optimal treatment outcomes. The ability of retail pharmacies to provide consistent medication refills and support makes them a key component in long-term patient care.

Hospital pharmacies remain crucial, especially in the initial stages of treatment, when close monitoring is essential. Parkinson's disease patients, for instance, often begin therapy under hospital supervision before transitioning to outpatient care. As patients stabilize, retail and specialty pharmacies become primary sources for continued medication access and support services, ensuring uninterrupted treatment for chronic neurological disorders.

As the demand for dopamine agonists continues to rise, challenges such as supply chain management and drug distribution will emerge. Ensuring the consistent availability of both oral and injectable therapies will require a strong logistics infrastructure and a focus on patient education to maximize adherence and therapeutic outcomes. Moreover, continued investment in research and development, particularly for novel delivery systems, presents an opportunity for pharmaceutical companies to cater to a broader patient population and enhance treatment effectiveness.

Dopamine Agonist Market Report Highlights:

  • In 2024, non-ergot dopamine agonists dominated the market, solidifying their position as the preferred treatment option for neurological disorders. Their superior safety profile, improved tolerability, and growing clinical acceptance make them the leading therapy in this class.
  • The oral segment dominated the market in 2024. Oral formulations are widely preferred due to their convenience, long-term adherence benefits, and effectiveness in managing chronic conditions like Parkinson's disease, restless legs syndrome (RLS), and hyperprolactinemia.
  • Retail pharmacies emerged as the dominant distribution channel in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using dopamine agonist medications.
  • North America led the market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Dopamine Agonist Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising prevalence of neurological disorders
      • 3.3.1.2. Growing geriatric population
      • 3.3.1.3. Advancements in drug formulations & delivery methods
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. Severe side effects & safety concerns
      • 3.3.2.2. Emerging alternative therapies
  • 3.4. Dopamine Agonist Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape
  • 3.5. Pipeline Analysis
    • 3.5.1. Phase 1
    • 3.5.2. Phase 2
    • 3.5.3. Phase 3

Chapter 4. Dopamine Agonist Market: By Drug Estimates & Trend Analysis

  • 4.1. Dopamine Agonist Market: Drug Segment Dashboard
  • 4.2. Dopamine Agonist Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Non-Ergot Dopamine Agonists
    • 4.3.1. Non-Ergot Dopamine Agonists Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Ergot Alkaloids
    • 4.4.1. Ergot Alkaloids Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Dopamine Agonist Market: Application Estimates & Trend Analysis

  • 5.1. Dopamine Agonist Market: Application Segment Dashboard
  • 5.2. Dopamine Agonist Market: By Application Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Parkinson's Disease
    • 5.3.1. Parkinson's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Restless Legs Syndrome (RLS)
    • 5.4.1. Restless Legs Syndrome (RLS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Hyperprolactinemia
    • 5.5.1. Hyperprolactinemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Dopamine Agonist Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Dopamine Agonist Market: Route of Administration Segment Dashboard
  • 6.2. Dopamine Agonist Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Oral
    • 6.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Injectable
    • 6.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Dopamine Agonist Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Dopamine Agonist Market: Distribution Channel Segment Dashboard
  • 7.2. Dopamine Agonist Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 7.3. Retail Pharmacies
    • 7.3.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Other Pharmacies
    • 7.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Dopamine Agonist Market: Regional Estimates & Trend Analysis

  • 8.1. Dopamine Agonist Market Share, By Region, 2024 & 2030 (USD Million)
  • 8.2. North America
    • 8.2.1. North America Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Reimbursement Framework
      • 8.2.2.5. U.S. Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Reimbursement Framework
      • 8.2.3.5. Canada Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Reimbursement Framework
      • 8.2.4.5. Mexico Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Framework
      • 8.3.2.5. Uk Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Framework
      • 8.3.3.5. Germany Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Reimbursement Framework
      • 8.3.4.5. France Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Reimbursement Framework
      • 8.3.5.5. Italy Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Reimbursement Framework
      • 8.3.6.5. Spain Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Reimbursement Framework
      • 8.3.7.5. Denmark Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Reimbursement Framework
      • 8.3.8.5. Sweden Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Reimbursement Framework
      • 8.3.9.5. Norway Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. Japan Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. China Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. India Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Framework
      • 8.4.5.5. Australia Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Framework
      • 8.4.6.5. South Korea Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Framework
      • 8.4.7.5. Thailand Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. Japan Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. China Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. Middle East and Africa Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. South Africa Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. Saudi Arabia Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. UAE Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Kuwait Dopamine Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis by Key Market Participants
  • 9.2. Company Categorization
  • 9.3. Participant Overview
  • 9.4. Financial Performance
  • 9.5. Product Bench Marking
  • 9.6. Company Market Share Analysis, 2024
  • 9.7. Company Profiles
    • 9.7.1. Teva Pharmaceutical Industries Ltd
      • 9.7.1.1. Participant's Overview
      • 9.7.1.2. Financial Performance
      • 9.7.1.3. Product Benchmarking
      • 9.7.1.4. Recent Developments/ Strategic Initiatives
    • 9.7.2. GSK plc.
      • 9.7.2.1. Participant's Overview
      • 9.7.2.2. Financial Performance
      • 9.7.2.3. Product Benchmarking
      • 9.7.2.4. Recent Developments/ Strategic Initiatives
    • 9.7.3. Supernus Pharmaceuticals, Inc.
      • 9.7.3.1. Participant's Overview
      • 9.7.3.2. Financial Performance
      • 9.7.3.3. Product Benchmarking
      • 9.7.3.4. Recent Developments/ Strategic Initiatives
    • 9.7.4. H. Lundbeck A/S
      • 9.7.4.1. Participant's Overview
      • 9.7.4.2. Financial Performance
      • 9.7.4.3. Product Benchmarking
      • 9.7.4.4. Recent Developments/ Strategic Initiatives
    • 9.7.5. Amneal Pharmaceuticals LLC
      • 9.7.5.1. Participant's Overview
      • 9.7.5.2. Financial Performance
      • 9.7.5.3. Product Benchmarking
      • 9.7.5.4. Recent Developments/ Strategic Initiatives
    • 9.7.6. UCB Pharma
      • 9.7.6.1. Participant's Overview
      • 9.7.6.2. Financial Performance
      • 9.7.6.3. Product Benchmarking
      • 9.7.6.4. Recent Developments/ Strategic Initiatives
    • 9.7.7. Novartis AG
      • 9.7.7.1. Participant's Overview
      • 9.7.7.2. Financial Performance
      • 9.7.7.3. Product Benchmarking
      • 9.7.7.4. Recent Developments/ Strategic Initiatives
    • 9.7.8. VeroScience LLC.
      • 9.7.8.1. Participant's Overview
      • 9.7.8.2. Financial Performance
      • 9.7.8.3. Product Benchmarking
      • 9.7.8.4. Recent Developments/ Strategic Initiatives
    • 9.7.9. Pfizer Inc.
      • 9.7.9.1. Participant's Overview
      • 9.7.9.2. Financial Performance
      • 9.7.9.3. Product Benchmarking
      • 9.7.9.4. Recent Developments/ Strategic Initiatives
    • 9.7.10. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 9.7.10.1. Participant's Overview
      • 9.7.10.2. Financial Performance
      • 9.7.10.3. Product Benchmarking
      • 9.7.10.4. Recent Developments/ Strategic Initiatives

Chapter 10. Conclusion

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 4 North America dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 5 North America dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
  • Table 6 North America dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 7 North America dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 10 U.S. dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 U.S. dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Canada dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
  • Table 14 Canada dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Canada dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 17 Mexico dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 18 Mexico dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Mexico dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Europe dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 23 Europe dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 Europe dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 UK dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 26 UK dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
  • Table 27 UK dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 UK dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 Germany dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 30 Germany dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 31 Germany dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Germany dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 France dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 34 France dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 35 France dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 France dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Spain dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 38 Spain dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 39 Spain dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 40 Spain dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Italy dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 42 Italy dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 43 Italy dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 Italy dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 46 Denmark dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 47 Denmark dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 48 Denmark dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Sweden dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 50 Sweden dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 51 Sweden dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Sweden dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Norway dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 54 Norway dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 55 Norway dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Norway dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Japan dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 63 Japan dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 64 Japan dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 65 Japan dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 China dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 67 China dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 68 China dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 69 China dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 India dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 71 India dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 72 India dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 India dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 South Korea dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 75 South Korea dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 76 South Korea dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 77 South Korea dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 Australia dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 79 Australia dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 80 Australia dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 81 Australia dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Thailand dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 83 Thailand dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 84 Thailand dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 Thailand dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Latin America dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 87 Latin America dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 88 Latin America dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 89 Latin America dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 90 Latin America dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91 Brazil dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 92 Brazil dopamine agonist market estimates and forecasts, by drug, 2018 - 2030 (USD Million)
  • Table 93 Brazil dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 94 Brazil dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Argentina dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 96 Argentina dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 97 Argentina dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 Argentina dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 MEA dopamine agonist market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 100 MEA dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 101 MEA dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 102 MEA dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 103 MEA dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104 South Africa dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 105 South Africa dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 106 South Africa dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 107 South Africa dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 UAE dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 109 UAE dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 110 UAE dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 111 UAE dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 Kuwait dopamine agonist market estimates and forecasts, by application, 2018 - 2030 (USD Million)
  • Table 117 Kuwait dopamine agonist market estimates and forecasts, by drugs, 2018 - 2030 (USD Million)
  • Table 118 Kuwait dopamine agonist market estimates and forecasts, by route of administration, 2018 - 2030 (USD Million)
  • Table 119 Kuwait dopamine agonist market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Dopamine agonist market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Application segment snapshot
  • Fig. 10 Drug and application segment snapshot
  • Fig. 11 Route of administration and distribution channel segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Pharmaceutical market, (USD Billion)
  • Fig. 14 Market dynamics
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTLE analysis
  • Fig. 17 Dopamine agonist market: Drug outlook and key takeaways
  • Fig. 18 Dopamine agonist market: Drug movement analysis
  • Fig. 19 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Non-ergot dopamine agonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Dopamine agonist market: Application outlook and key takeaways
  • Fig. 22 Dopamine agonist market: Application movement analysis
  • Fig. 23 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Restless Legs Syndrome (RLS) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Hyperprolactinemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Dopamine agonist market: Route of administration outlook and key takeaways
  • Fig. 28 Dopamine agonist market: Route of administration movement analysis
  • Fig. 29 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Dopamine agonist market: Distribution channel outlook and key takeaways
  • Fig. 33 Dopamine agonist market: Distribution channel movement analysis
  • Fig. 34 Retail pharmacies market estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Other pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Dopamine agonist market revenue, by region, 2024 & 2030, (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America dopamine agonist market estimates and forecasts, 2018 - 2030 ((USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 Target disease prevalence
  • Fig. 43 U.S. dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Target disease prevalence
  • Fig. 46 Canada dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Mexico dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 Europe dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Target disease prevalence
  • Fig. 53 UK dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Target disease prevalence
  • Fig. 56 Germany dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Target disease prevalence
  • Fig. 59 France dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Target disease prevalence
  • Fig. 62 Spain dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Target disease prevalence
  • Fig. 65 Italy dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Target disease prevalence
  • Fig. 68 Denmark dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Target disease prevalence
  • Fig. 71 Sweden dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Target disease prevalence
  • Fig. 74 Norway dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Rest of Europe dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Asia Pacific dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Target disease prevalence
  • Fig. 79 Japan dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 Target disease prevalence
  • Fig. 82 China dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Target disease prevalence
  • Fig. 85 India dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 Target disease prevalence
  • Fig. 88 Australia dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Thailand dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 South Korea dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Rest of Asia Pacific dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Latin America dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Target disease prevalence
  • Fig. 97 Brazil dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 Target disease prevalence
  • Fig. 100 Argentina dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Rest of Latin America dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 MEA dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Target disease prevalence
  • Fig. 105 South Africa dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Target disease prevalence
  • Fig. 108 Saudi Arabia dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 Target disease prevalence
  • Fig. 111 UAE dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Key country dynamics
  • Fig. 113 Target disease prevalence
  • Fig. 114 Kuwait dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Rest of MEA dopamine agonist market estimates and forecasts, 2018 - 2030 (USD Million)